10 Best Gene Therapy Stocks to Buy in 2026

7. MeiraGTx Holdings PLC (NASDAQ:MGTX)

Stock Upside Potential: 116.22%

Number of Hedge Fund Holders: 23

MeiraGTx Holdings PLC (NASDAQ:MGTX) is one of the best gene therapy stocks to buy in 2026. The stock has gained around 25% year-to-date and soared more than 95% over the past year. Looking ahead, analysts believe the stock could explode more than 100% in the next 12 months as MeiraGTx advances its various therapy programs.

MeiraGTx reported its Q1 2026 financial and operational results on May 14. Regarding financials, the company expects its cash runway to extend into the second half of 2028. It said that it exited Q1 with $71.5 million in cash and expects to receive $14.7 million in tax incentives.

The company has also launched an equity offering to raise around $100 million. Additionally, MeiraGTx expects to receive $95 million in upfront payments from its deal Hologen, a joint venture partner.

Regarding its therapy programs, MeiraGTx said it is on pace to launch two therapies in the next two years. The company highlighted positive results from a Phase 1 study of AAV2-hAQP1, a potential therapy for patients with xerostomia. This program has recently received the FDA’s Breakthrough Therapy Designation, which MeiraGTx says supports potential accelerated development and regulatory pathway.

MeiraGTx also said that it acquired full rights to bota-vec from Johnson and Johnson. Bota-vec is a late-stage program being developed as a therapy for X-linked retinitis pigmentosa.

MeiraGTx Holdings PLC (NASDAQ:MGTX) is a biotech company focused on genetic medicine. It develops gene therapies for both rare and common diseases. It targets ocular, neurodegenerative, and metabolic disorders.